SK Biopharmaceuticals Co., Ltd.
326030
Rangering i aksjer
#4041
SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the... SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the research, identification, and development of novel therapies for central nervous system (CNS) disorders. Their product portfolio features Cenobamate, indicated for the treatment of epilepsy, and Solriamfetol, which addresses excessive daytime sleepiness experienced in conditions like narcolepsy or obstructive sleep apnea. The company's robust clinical pipeline includes Carisbamate, currently in Phase 1b/2 trials for Lennox-Gastaut syndrome, and Relenopride, advancing through Phase 2 for a rare neurological disease. Additionally, they have several candidates in Phase 1 development: SKL13865 for attention deficit/hyperactivity disorder (ADHD), SKL20540 for schizophrenia, SKL-PSY for bipolar disorder, and SKL24741, another potential treatment for epilepsy. Founded in 2011, the company is headquartered in Seongnam, South Korea, and functions as a subsidiary of SK Inc.
Aksjekurs
$51.65
Markedsverdi
$4.05B
Endring (1 dag)
0.27%
Endring (1 år)
-30.95%
Land
KR
Handel SK Biopharmaceuticals Co., Ltd. (326030)
Kategori
Healthcare
Antall utestående aksjer for SK Biopharmaceuticals Co., Ltd. (326030)
Antall utestående aksjer per June 2026: 78.31M
Ifølge SK Biopharmaceuticals Co., Ltd. sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 78.31M. Ved slutten av December 2024 hadde selskapet 78.31M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for SK Biopharmaceuticals Co., Ltd. (326030) fra 2011 til 2026
Utestående aksjer ved utgangen av hvert år
| År | Utestående aksjer | Endre |
|---|---|---|
| 2026 (TTM) | 78.31M | -100.00% |
| 2025 | 0.00 | -100.00% |
| 2024 | 78.31M | 0.00% |
| 2023 | 78.31M | 0.00% |
| 2022 | 78.31M | 0.00% |
| 2021 | 78.31M | 9.12% |
| 2020 | 71.77M | 10.41% |
| 2019 | 65.00M | 4.44% |
| 2018 | 62.23M | 24.47% |
| 2017 | 50.00M | -0.04% |
| 2016 | 50.02M | 0.04% |
| 2015 | 50.00M | 1.08% |
| 2014 | 49.46M | 23.66% |
| 2013 | 40.00M | -0.03% |
| 2012 | 40.01M | 0.11% |
| 2011 | 39.97M | 0.00% |
Utestående aksjer for lignende selskaper eller konkurrenter
| Selskap | Utestående aksjer | Forskjell | Land |
|---|---|---|---|
| 253.90M | 224.21% |
US
|
|
| 396.00M | 405.66% |
US
|
|
| 478.91M | 511.54% |
AU
|
|
| 62.19M | -20.59% |
NL
|
|
| - | - |
CH
|
